From 2022 to 2032, the global market for treating benign prostatic hyperplasia (BPH) is projected to increase at a compound annual growth rate (CAGR) of 5%, from its 2021 valuation of US$27.7 billion.  By the end of 2032, the global market for treatments for benign prostatic hyperplasia (BPH) is projected to be valued at US$47.17 billion. Benign Prostatic Hyperplasia, commonly known as...